Dissemination of high-risk clones of extensively drug-resistant pseudomonas aeruginosa in Colombia
| Autor: | Victor M. Blanco, Maria V. Villegas, Federico Perez, Rosa del Campo, Mercedes Rodríguez-Baños, Laura J. Rojas, Adriana Correa, Rafael Cantón, Marcela Perenguez, Juan J. Maya, Cesar A. Arias |
|---|---|
| Přispěvatelé: | Merck Sharp & Dohme de España, Pfizer, AstraZeneca, Novartis, European Commission, Instituto de Salud Carlos III, Villegas, María Virginia [0000-0003-1898-9067] |
| Rok vydání: | 2015 |
| Předmět: |
Transposable element
Clonal dissemination Drug resistance Microbial Sensitivity Tests Biology Colombia medicine.disease_cause Integron beta-Lactamases Microbiology Bacterial protein Bacterial Proteins Mechanisms of Resistance Drug Resistance Multiple Bacterial medicine Humans Pharmacology (medical) Pseudomonas Infections Farmacorresistencia bacteriana Pharmacology Cross Infection Pseudomonas aeruginosa Antimicrobial Infecciones por pseudomonas 3. Good health Anti-Bacterial Agents Clone Cells Infectious Diseases biology.protein Mobile genetic elements |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Repositorio U. El Bosque Universidad El Bosque instacron:Universidad El Bosque |
| Popis: | The ability of Pseudomonas aeruginosa to develop resistance to most antimicrobials represents an important clinical threat worldwide. We report the dissemination in several Colombian hospitals of two predominant lineages of extensively drug-resistant (XDR) carbapenemase-producing P. aeruginosa strains. These lineages belong to the high-risk clones sequence type 111 (ST111) and ST235 and harbor blaVIM-2 on a class 1 integron and blaKPC-2 on a Tn4401 transposon, respectively. Additionally, P. aeruginosa ST1492, a novel single-locus variant of ST111, was identified. Clonal dissemination and the presence of mobile genetic elements likely explain the successful spread of XDR P. aeruginosa strains in Colombia. This work was supported by Merck Sharp & Dohme, Janssen-Cilag SA, Pfizer SA, AstraZeneca Colombia SA, Merck Colombia, Novartis, Amarey Novamedical, Merck S.A, and bioMérieux Colombia, which help fund the Colombian Nosocomial Resistance Study Group (CNRSG). The research of Rafael Cantón at the Microbiology Department of Ramón y Cajal University Hospital is funded by the European Commission (grants R-GNOSIS-FP7-HEALTH-F3-2011-282512 and FP7-HEALTH-F3-2013-MON4STRAT-602906-2) and the Instituto de Salud Carlos III of Spain, cofinanced by the European Development Regional Fund (A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|